Sign up
BBOT

BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. Short interest is 9.68% of float with a 0.68% borrow fee. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 32.6 (overbought above 70, oversold below 30)

Trend—

—

Short interest9.7% of float

FINRA settlement Oct 30, 2026

BBOT price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range
$1.81 – $13.69Through Nov 18, 2026
Volume—
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$171.74M
P/E (TTM)4.1
Forward P/E—
EPS (TTM)eps split basis unknown —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

BBOT · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze43Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

EPS, last 3 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.66−$0.43—
Annual 2025—−$4.30—
Q3 2025—−$1.03—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All BBOT news →

Company profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small

CEO
Dr. Pedro J. Beltran M.D., Ph.D.
Headquarters
South San Francisco, CA, United States
Employees
92
IPO date
Aug 12, 2025
Sector
Healthcare
Industry
Biotechnology
Website
bbotx.com

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.